Dr Reddy's Laboratories inks licensing pact with US' Slayback Pharma

Dr Reddy's Laboratories on Saturday said it has entered into a pact with US-based Slayback Pharma to acquire rights of a medication to relieve redness of the eyes

Dr Reddy's
Dr Reddy's
Press Trust of India New Delhi
1 min read Last Updated : Jul 30 2022 | 3:51 PM IST

Dr Reddy's Laboratories on Saturday said it has entered into a pact with US-based Slayback Pharma to acquire rights of a medication to relieve redness of the eyes.

The company has inked a licensing pact with the NewJersey-based drug firm to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025 per cent, the Hyderabad-based firm said in a statement.

The company's product is equivalent to Lumify, an over-the-counter (OTC) eyedrop, that can be used to relieve redness of the eye due to minor eye irritations.

The agreement also provides Dr Reddy's exclusive rights to the product outside the US, Dr Reddy's Laboratories said.

As per industry estimates, the value of the total addressable market for this product in the US is around USD 130 million for the 52 weeks ending June 12, 2022.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr ReddysUnited StatesPharma Companies

First Published: Jul 30 2022 | 3:30 PM IST

Next Story